India–EU FTA Boosts Pharma And MedTech Trade

The FTA is expected to unlock access to the EU’s Rs 572.3 billion pharmaceuticals and medical devices market, providing significant momentum to India’s pharmaceutical industry. The agreement is likely to support industry scaling, employment generation and stronger integration into global supply chains, while reinforcing India’s position as a reliable partner in the global pharmaceuticals sector.

The deal is expected to drive growth in high-value segments through preferential market access and liberalised tariffs for key ‘Made in India’ medical devices. It is also set to stimulate expansion across inorganic and organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents. Capacity expansion, MSME cluster development and increased participation of smaller enterprises are expected to further strengthen sectoral growth.

The FTA is likely to create major expansion opportunities across industrial hubs in Gujarat, Maharashtra, Karnataka and Andhra Pradesh. Coastal export hubs are expected to scale export-led growth, supporting employment and processing-intensive industries. Aligned with India’s vision of “Viksit Bharat 2047”, the India–EU FTA is positioned to foster innovation and lay the foundation for inclusive, resilient and future-ready growth for both India and Europe.

Commenting on the agreement, Union Minister for Chemicals and Fertilisers J P Nadda said that the India–EU FTA opens new opportunities for pharmaceuticals and medical devices, with improved access to the EU’s Rs 572.3 billion pharma and MedTech market and liberalised tariffs expected to accelerate growth in high-value sectors. He added that India continues to strengthen its presence as a reliable global partner in healthcare and manufacturing.